 |
|
|
|
|
Experimental Cancer Vaccines Show Promise
They target malignancies of the cervix, prostate and breast, among others
By Amanda Gardner
HealthDay Reporter
|
| | | | Related Healthscout Videos | |
|
TUESDAY, April 15 (HealthDay News) -- A germ that commonly causes food poisoning may be the next weapon in the fight against cervical cancer, a major cause of death among women worldwide.
A new trial shows that a live Listeria vaccine called Lovaxin C is safe and even showed some benefit in 15 women with advanced cervical cancer.
Text Continues Below
Listeria is a common bacteria found on leafy vegetables and dairy products. "Most of us eat it routinely but don't know it, because it generates a strong immune reaction," study lead author John Rothman, vice president of clinical development at Advaxis Inc. of North Brunswick, N.J., which makes the vaccine, said at a Tuesday news conference. "It can cause disease, but it's safe, because the lowest doses of any number of antibiotics will clear it and will do it without impeding the immune response."
This vigorous immune response is what researchers are hoping will give the vaccine a fighting chance against cervical cancer. According to Rothman, there are at least 10 ways that Listeria attacks tumors, and probably more.
Most of the women involved in this study had stage 4 disease and had failed prior surgery, chemotherapy or radiation. All women were given the vaccine as well as the antibiotic ampicillin.
By study's end, only five patients still had progressive disease, seven were stable and one demonstrated a partial response to the vaccine. Three of the seven stable patients showed tumor reductions of about 20 percent and one of more than 30 percent.
The vaccine did cause flu-like symptoms in all patients (fever, chills, nausea), but those who had received lower-dose vaccines were treated easily with over-the-counter drugs, the researchers said.
Rothman's study was just one of several showing promise that were presented Tuesday at the American Association for Cancer Research annual meeting, in San Diego.
Page: 1 | 2 | Next >>
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/15/2008
|
|
SOURCES: April 15, 2008, teleconference with John Rothman, Ph.D., vice president of clinical development, Advaxis Inc., North Brunswick, N.J.: Saskia Santegoets, VU University Medical Center, Amsterdam, the Netherlands; Lawrence Fong, M.D., University of California, San Francisco; American Association for Cancer Research annual meeting, San Diego
|
.gif)
